CCD 3693

Drug Profile

CCD 3693

Alternative Names: CO 32693

Latest Information Update: 23 Dec 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Purdue Pharma
  • Class Sleep disorder therapies
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Insomnia

Most Recent Events

  • 23 Dec 2002 Discontinued - Phase-I for Insomnia in Europe (unspecified route)
  • 13 Aug 1998 Agreement between CoCensys and Searle to collaborate on development of CCD 3693 has been terminated
  • 06 Mar 1998 Phase-I clinical trials for Insomnia in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top